Brian Mathew

I refer the honourable member to my previous answer dated 20/01/2025 [UIN 23400].

Both the UK and the EU allow for visa-free short-term travel in line with their respective arrangements for third country nationals. The UK allows EU citizens short-term, visa-free travel for up to six months. Meanwhile, the Schengen Borders Code allows for certain third country nationals to travel within the Schengen Area for up to 90 days in any 180-day period; this is standard for third-country nationals travelling to the EU.  The UK Government will continue to listen to and advocate for UK nationals.

Our priority is the effective implementation of the Online Safety Act so that children benefit from its wide-reaching protections.

The Act requires all services in scope to protect all users, including children, from illegal content and criminal behaviour. Services likely to be accessed by children will also need to provide additional safety measures to protect them from harmful and age-inappropriate content.

Services will need to start complying with their illegal content duties from March and the child safety duties by the summer.

The responsible body, relevant local authority, academy trust or voluntary-aided body, is responsible for ensuring the health, safety and welfare of pupils when in their care including meeting any relevant standards for internal environments.

The department publishes non-statutory guidance on indoor air quality in ‘Building Bulletin 101: Guidelines on ventilation, thermal comfort and indoor air quality in schools’ (BB101), which can be found here: https://www.gov.uk/government/publications/building-bulletin-101-ventilation-for-school-buildings.

All new department-delivered schools are designed and constructed to the department’s school building standards. These standards cover ventilation and can be found here: https://www.gov.uk/government/publications/employers-requirements-part-b-generic-design-brief.

Cleaning up our waters, including iconic sites such as chalk streams is a top government priority. That is why on 23 October 2024, the Secretary of State announced the launch of an independent commission to fundamentally transform how our water system works.

Fixing the systemic issues in the water system is essential to address the multiple pressures facing chalk streams, namely over abstraction, phosphorous pollution and physical modifications of habitats. Restoring our chalk streams to better ecological health is part of our holistic programme of reforms for the water sector.

Alongside this, we are continuing to direct investment to projects that will improve chalk streams. In 2024/2025, there are over 45 chalk stream projects receiving funding from the Government's Water Environment Improvement Fund, each leveraging private investment.

As Biodiversity Net Gain (BNG) has recently passed the one year anniversary since it went live for most major development in England, I can confirm that this Government is fully committed to making BNG work effectively to protect our natural world.

The Government has confirmed its commitment to delivering the Collection and Packaging Reforms to the announced timelines, subject to spending review. The reforms will mean that people across England will be able to recycle the same materials, whether at home, work or school. This will include a weekly food waste collection for every household and, from March 2027, kerbside collections of plastic film packaging. Separately, packaging Extended Producer Responsibility will place a charge on all household packaging that is placed on the market, including plastic film, to cover the local authority costs of its collection, treatment and disposal.

Together with mechanical recycling, chemical recycling technologies play a role in enabling the transition towards a circular economy. The government is aware that some stakeholders with an interest in chemically recycling plastic film are keen that a mass balance approach is used to calculate chemically recycled content in plastic packaging for the purposes of the Plastic Packaging Tax. His Majesty’s Treasury consulted on the incorporating of mass balance into the Plastic Packaging Tax in October 2023 and are preparing to publish their response before the end of the year.

We are working closely with all operators to improve performance as it is the key focus for the Secretary of State. The Department is also working with Great Western Railway to provide a more robust service for Wiltshire and Melksham through improved rolling stock reliability and train crew availability. Performance in the last couple of periods has improved since carrying out significant improvement works around Westbury and driver related cancellations on Sundays have also reduced.

Future rail infrastructure investment will be considered as part of the current Spending Review, which will conclude in June 2025.

Officials and National Highways are exploring all funding options for the Lower Thames Crossing, including private finance. As with all capital projects, spending decisions will be subject to the upcoming spending review. The assured cost estimate in line with the 2023 baseline for publicly funding the project is £8.95bn, but it is important to recognise that there is a normal level of uncertainty at this early stage of the development of a project of the size and complexity of the Lower Thames Crossing.

The Department funds rare disease research through the National Institute for Health and Care Research (NIHR). 17 NIHR Biomedical Research Centres support research into rare diseases and the NIHR is working in partnership with the Medical Research Council to co-fund a UK Rare Disease Research Platform which brings together research teams across the United Kingdom with patients, stakeholders and technologies to deliver rare disease research with greater impact.

Genomic testing in the National Health Service in England is provided through the NHS Genomic Medicine Service and delivered by a national genomic testing network of seven NHS Genomic Laboratory Hubs (GLHs). The NHS GLHs deliver testing as directed by the National Genomic Test Directory, which includes tests for over 7,000 rare diseases and over 200 clinical indications of cancer. Testing can be delivered using a range of technologies, including whole genome sequencing (WGS) or Next Generation Sequencing technology, large cancer gene panels, to ensure that a patient receives the most appropriate genomic testing depending on their individual circumstances.

The National Genomic Test Directory sets out the eligibility criteria for patients to access testing as well as the genomic targets to be tested and the method that should be used. For most cancers, the National Genomic Test Directory outlines that large gene panels inclusive of targets for treatments should be offered as the first line option. WGS can then be offered to any cancer patient that requires it to determine their next stage of treatment.

Improvements in genomic capabilities have accelerated the development of new precision medicines which can target genomic mutations, including for rare cancers. To help make precision medicines available to patients, the National Health Service has supported access to clinical trials, where the eligibility is based on genomic variants. They also support the adoption and spread of innovative medicines through an innovative genomic testing service and commercial medicines framework.

In October 2022, NHS England published the first NHS Genomics Strategy, Accelerating Genomic Medicine in the NHS, which outlines the vision for embedding genomics in the NHS over the next five years. The strategy includes a commitment to work with partners, including the National Institute for Health and Care Excellence and the Medicines and Healthcare products Regulatory Agency, to identify and prepare for the rapid introduction of companion diagnostic genomic testing. This is critical to ensuring easy access to innovative precision medicines and technologies. Further information on Accelerating Genomic Medicine in the NHS is available at the following link:

https://www.england.nhs.uk/wp-content/uploads/2022/10/B1627-Accelerating-Genomic-Medicine-October-2022.pdf

Additionally, the National Cancer Plan will include further details on how we will improve outcomes for cancer patients, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, including genetic treatments.

Too many children and young people are not receiving the mental health care they need, and we know that waits for mental health services are far too long. We are determined to change that. We will recruit 8,500 additional mental health workers across children and adult services to reduce delays and provide faster treatment. We will also provide access to a specialist mental health professional in every school in England and introduce open access Young Futures hubs in every community.

It is the responsibility of integrated care boards (ICBs) to make available appropriate provision to meet the health and care needs of their local population, including autism and attention deficit hyperactivity disorder (ADHD) services, in line with relevant National Institute for Health and Care Excellence guidelines.

In April 2023, NHS England published a national framework and operational guidance to help ICBs and the National Health Service to deliver improved outcomes for children, young people and adults referred to an autism assessment service. In 2024/25, £4.3 million is available nationally to improve services for autistic children and young people, including autism assessment services.

We are supporting a taskforce that NHS England has established to look at ADHD service provision and its impact on patient experience. The taskforce is bringing together expertise from across a broad range of sectors, including the NHS, education and justice, to better understand the challenges affecting people with ADHD including timely access to services and support.

In conjunction with the taskforce, NHS England is carrying out detailed work to develop a data improvement plan, understand the provider and commissioning landscape and capture examples from ICBs who are trialling innovative ways of delivering ADHD services.

The resilience of the United Kingdom’s supply chains is a key priority, and we are committed to helping build long term supply chain resilience for medicines. The Department works in partnership with industry, the National Health Service, and the wider health system to help ensure the continuity of the supply of medical products, including for attention deficit hyperactivity disorder (ADHD) medicines. These issues are often global in nature. We monitor and manage medicine supply issues at a national level, so that stocks remain available to meet regional and local demand, and therefore there are no specific measures for the West Midlands.

As a result of intensive work, some issues with ADHD medicines have been resolved. All strengths of lisdexamfetamine, atomoxetine capsules, atomoxetine oral solution, and guanfacine prolonged-release tablets are now available.

However, whilst the supply of methylphenidate prolonged-release tablets has improved, issues still persist. We are continuing to work to resolve these remaining issues by engaging with all suppliers of methylphenidate prolonged-release tablets to assess the challenges faced and their actions to address them. We are also directing suppliers to secure additional stocks, expedite deliveries where possible, and review plans to further build capacity to support the continued growth in demand for the short and long-term. The Department is also working with new suppliers of methylphenidate prolonged-release tablets to improve supply and resiliency for the UK market.

We are supporting an ADHD taskforce that NHS England has established to examine ADHD service provision. The taskforce will bring together expertise from across a broad range of sectors, including the NHS, education, and justice, to help provide a joined-up approach in response to concerns around rising demand. In collaboration with NHS England’s national ADHD data improvement plan, we plan to combine modelling for future growth forecasts, which will be shared with industry to improve demand forecasting for ADHD medicines.

The Department has worked with NHS specialists to develop advice on prescribing alternative ADHD medications. We expect that ADHD service providers should follow this guidance and offer rapid responses for urgent advice, especially for high-risk patients. To aid decision-making at the point of the prescribing and dispensing of ADHD medicines, we continue to update a list of available ADHD products on the Specialist Pharmacy Service website.

Rachel Kyte CMG and Ruth Davis OBE were appointed as the UK's Special Representatives for Climate and for Nature, respectively, on 21 October and 15 November.

Their biographies and objectives are set out at https://www.gov.uk/government/people/rachel-kyte and https://www.gov.uk/government/people/ruth-davis.

These roles are covered by wider Foreign, Commonwealth and Development Office (FCDO), Department for Energy Security and Net Zero (DESNZ) and Department for Environment Food and Rural Affairs (DEFRA) budgets. The Special Representatives have agreed priorities with departments, which are being implemented.

The Ukraine Permission Extension Scheme opened to applications on 4 February 2025, which enables Ukrainians in the UK under the Ukraine visa schemes to apply for a further 18 months’ temporary permission to remain in the UK.  Further information on eligibility and application processes is available at Applying to the Ukraine Permission Extension scheme - GOV.UK.

Applicants who still have their BRP may be able to reuse previously submitted biometrics (fingerprint and photograph) and may not need to attend a UK Visas and Citizenship Application (UKVCAS) service point. Applicants that apply before their current permission expires will retain the conditions of their current visa whilst their application is under consideration, and these conditions are demonstrated on an applicant’s eVisa.

At present there are no plans to supply additional Challenger 2 tanks to Ukraine.

The UK's decision to send a squadron of 14 Challenger 2 Main Battle Tanks to Ukraine in 2023 delivered a coherent and combat effective capability and spearheaded the provision of dozens of additional Western Main Battle Tanks from international partners.

We recently announced we will be providing Ukraine with more than 50 armoured and protected vehicles, including modernised T-72 tanks, by the end of spring, building on over 1,000 armoured, protected and logistics vehicles the UK has previously delivered to Ukraine.

We continue to work closely with the Ukrainian Government to ensure the capabilities we provide meet the priorities of the Armed Forces of Ukraine.

Russia has publicly admitted to the use of Riot Control Agents on the battlefield against Ukraine, and there are multiple reports of the use of the toxic choking agent chloropicrin. In December last year, a Technical Report confirming the use of Riot Control Agents in Ukraine was published by the Organisation for the Prohibition of Chemical Weapons.

The UK has been at the forefront of international support and assistance to Ukraine. In the first few months of Russia's illegal invasion, UK Ministry of Defence (MOD) provided respirators and decontamination kits to the Armed Forces of Ukraine, as well as other protective measures to enhance Ukraine's protective capabilities against chemical weapons.

In December 2024, following a direct request for UK Assistance by Ukraine, the MOD announced further funding for the procurement of respirators and other equipment to protect Ukraine's forces. This is being procured jointly with international partners through the G7 led Global Partnership Against the Spread of Weapons of Mass Destruction.

Our commitment to Ukraine is unwavering and we continue to work closely with our international partners, both bilaterally and in multilateral forums, to coordinate counter-CBRN support and assistance to Ukraine.

The revised National Planning Policy Framework (NPPF) published on 12 December 2024 is clear as to the important role that neighbourhood plans play in the planning system and includes important protections for neighbourhood plans from speculative development.

Once passed at referendum, neighbourhood plans form part of the development plan, which is the starting point in making planning decisions.

The revised NPPF is clear that where a planning application conflicts with policies in an up-to-date local plan or neighbourhood plan, the application should not usually be granted.

The National Planning Policy Framework sets out that to protect and enhance biodiversity and geodiversity, local plans should identify, map and safeguard components of local wildlife-rich habitats and wider ecological networks such as chalk streams. It is for local planning authorities to apply this policy when planning for new development.

Chalk streams are specifically referenced in the definitions of ‘natural environment’ and ‘environmental protection’ for the new system of Environmental Outcomes Reports that the government intend to introduce. This will ensure the protection of chalk streams is taken into account as part of this new approach to environmental assessment.

The government will consult on draft regulations in due course following policy development and engagement with key stakeholders. While we want to realise the benefits of reform as quickly as possible, we recognise the need to manage the transition to the new system carefully. Until a new system is implemented, current legislation on environmental assessment and its supporting guidance continues to apply.

I refer the hon. Member to the answer given to Question UIN 25804 on 10 February 2025.

In "designated rural areas" properties cannot be sold under the Right to Acquire so as to preserve social housing in perpetuity for local people. The government has no plans to change this.

National planning policy is clear that development should be directed to areas with the lowest possible flood risk from all sources, including from the sea.

Where development is proposed in areas at risk of the impacts of coastal change, development should not be approved unless it can be demonstrated that it will be safe for its lifetime.

Development proposals would have to pass these robust tests to proceed in such locations.